Anuh Pharma Ltd. — Earnings Release 2026

May 20, 2026

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,

Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.

Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500

Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586

Web: www.anuhpharma.com

Date: 20th May, 2026

To,

The Manager (Listing)

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort, Mumbai - 400 001

BSE Scrip Code: 506260

To,

Listing Compliance Department

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1, G Block,

Bandra-Kurla Complex,

Bandra (East), Mumbai - 400051

NSE Symbol: ANUHPHR; Series: EQ

Subject: Outcome of Board Meeting dated, 20th May, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors of Anuh Pharma Limited (the Company) at its meeting held today, Wednesday, 20th May, 2026, has inter alia considered and approved the following:

1. The Audited Financial Results quarter and financial year ended 31st March 2026 (annexed as Annexure – A);
2. Statutory Auditor's Report on quarterly and year to date Financial results for the year ended 31st March, 2026. (annexed as Annexure – B);
3. Declaration regarding Audit Report with unmodified opinion to the Audited Financial Results for the financial year ended 31st March, 2026;
4. Recommendation of Dividend of Rs. 1.50/- per Equity share, amounting to a 30% payout on the face value of Rs. 5/- each for the Financial Year ended 31st March, 2026. The proposed dividend is subject to Shareholder's approval at the ensuing Annual General Meeting (AGM) of the Company;
5. Re-appointment of Mr. Bipin Nemchand Shah (DIN: 00083244), a director liable to retire by rotation.

Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (annexed as Annexure – C);

1. Re-appointment of Mr. Arun Lalchand Todarwal (DIN: 00020916), a director liable to retire by rotation.

Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (annexed as Annexure – D);

SK

We Serve Since 1932

Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.
Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500
Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586
Web: www.anuhpharma.com

1. Appointment of Mr. P. N. Rao as General Manager - Quality of the Company
   Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (annexed as Annexure - E);

2. Appointment of M/s. RMJ & Associates LLP, Chartered Accountants as Internal Auditors for the Financial Year 2026-27.
   Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (annexed as Annexure - F);

3. Re-appointment of Ankit Kishor Chande, Cost Accountant as Cost Auditor for the financial year 2026-27;
   Disclosure required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (annexed as Annexure - G);

4. Approval of Adoption of new set of Memorandum of Association ("MOA") of the Company as per Companies Act, 2013, subject to approval of the shareholders

5. Approval of Adoption of new set of Articles of Association ("AOA") of the Company as per Companies Act, 2013, subject to approval of the shareholders

6. Grant of authorisation to Key Managerial Personnel for determine the materiality of events or information and to make disclosures to the Stock Exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (annexed as Annexure - H).

7. The requests received from the following Shareholders forming part of Promoter Group of the Company seeking re-classification of their Status from "Promoter Group" into "Public" category under Regulation 31A of SEBI LODR Regulation:

Sr No.	Name	Number of Equity shares held	% of shareholding
1.	Madhurika Narendra Shah	12,000	0.01
2.	Hemant Babubhai Choksi	24,000	0.02
3.	Mukesh Kantilal Shah	14,400	0.01
4.	Aruna Navnit Shah	5,040	0.01
5.	Vikram Kirtilal Shah	200	0.00
6.	Kiran Piyush Shah	15,388	0.02
7.	Kinjal Siddharth Jhaveri	8,16,160	0.81
8.	Nina Vijay Shah	60,000	0.06
9.	Neela Pradeep Shah	2,800	0.003
TOTAL		9,49,988	0.95

SEK
We Serve Since 1932
Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,

Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.

Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500

Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586

Web: www.anuhpharma.com

1. The Draft Director's Report along with annexure for the Financial Year 2025-26;

2. The Draft Notice of 66th Annual General Meeting along with Explanatory Statement of the Company;

3. The 66th Annual General meeting will be held on Wednesday, 12th August, 2026, through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM");

4. Appointment of Mr. Pramod S. Shah, Partner of Pramod S. Shah & Associates, as Scrutinizer for 66th Annual General meeting;

5. The Register of Members and Share Transfer Books of the Company will remain closed from 06th August, 2026 to 12th August, 2026 (both days inclusive) for the purpose of Annual General Meeting and for the purpose Dividend, if approved by members;

6. The Record date for the purpose of determining the eligibility of shareholders for receiving the final dividend for F.Y. 2025-2026, if declared and approved by the members at the AGM and for determining the eligible shareholders entitled to vote through remote e-voting facility or at the Annual General Meeting has been fixed as Wednesday, 05th August, 2026;

7. The Adoption of the Policy for Implementation of NFRA circular;

The Meeting of the Board of Directors commenced at 02:00 p.m. and concluded at 09:10 p.m.

Kindly take the above on your records.

Thanking you,

Yours faithfully,

FOR ANUH PHARMA LIMITED

MANAN
JAYESH
VADHAN

Digitally signed
by MANAN
JAYESH VADHAN
Date: 2026.05.20
21:32:00 +05'30'

MANAN VADHAN
COMPANY SECRETARY & COMPLIANCE OFFICER
Encl: a/a

SK

We Serve Since 1932

Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

Annexure - A

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2026

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 31/03/2026	3 months ended 31/12/2025	3 months ended 31/03/2025	12 months ended 31/03/2026	12 months ended 31/03/2025
		Audited (Refer Note No 7)	Unaudited	Audited (Refer Note No 7)	Audited	Audited
(1)	(2)	(3)	(4)	(5)	(6)	(7)
I	Revenue from operations	20,211.72	19,717.81	19,813.95	77,165.74	66,151.49
II	Other income (Refer Note No-8)	(125.46)	178.72	139.83	435.56	945.53
III	Total Revenue (I + II)	20,086.26	19,896.53	19,953.78	77,601.30	67,097.02
IV	Expenses:
	Cost of materials consumed	14,071.39	11,431.40	13,791.68	51,044.32	46,327.71
	Purchases of Stock-in-Trade	282.87	3,148.00	1,092.50	7,919.67	3,854.64
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	768.33	548.34	(38.30)	1,002.09	(245.44)
	Employee benefits expense	634.93	691.06	684.62	2,630.33	2,303.92
	Finance costs	10.58	7.96	3.35	47.23	61.93
	Depreciation and amortization expense	300.29	300.25	275.60	1,138.22	873.94
	Other expenses	2,465.92	1,986.70	2,416.36	8,397.30	7,819.79
	Total expenses (IV)	18,534.31	18,113.71	18,225.81	72,179.16	60,996.49
V	Profit / (Loss) before exceptional and items and tax (III - IV)	1,551.95	1,782.82	1,727.97	5,422.14	6,100.53
VI	Exceptional items	-	-	-	-	-
VII	Profit / (Loss) before tax (V - VI)	1,551.95	1,782.82	1,727.97	5,422.14	6,100.53
VIII	Tax expenses:
	(1) Current tax	496.10	493.00	484.00	1,518.10	1,467.00
	(2) Deferred tax	(91.73)	(59.66)	(59.29)	(184.39)	(165.22)
	(3) Income tax of earlier years	(20.56)	4.38	57.56	(16.18)	63.56
	Total Tax expenses (VIII)	383.81	437.72	482.27	1,317.53	1,365.34
IX	Profit/(Loss) after Tax (VII-VIII)	1,168.14	1,345.10	1,245.70	4,104.61	4,735.19
X	Other Comprehensive Income
	(i) Items that will not be reclassified to profit or loss	(39.22)	60.87	13.73	24.73	(2.27)
	(ii) Income Tax relating to the items that will not be reclassified to profit or loss	9.88	(15.32)	(3.46)	(6.22)	0.57
	(iii) Items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income (net of Tax) (X) (net of Tax)	(29.34)	45.55	10.27	18.51	(1.70)
XI	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	1,138.80	1,390.65	1,255.97	4,123.12	4,733.49
	Paid up Equity Share Capital (Face value Rs. 5/- each) (Refer note no. 4)	5,011.20	5,011.20	2,505.60	5,011.20	2,505.60
	Other Equity (excluding revaluation reserves)	-	-		30,211.04	30,096.88
XII	Earnings per equity share (For respective periods) (In Rs.) (Refer note no. 4)
	(1) Basic	1.17	1.34	1.24	4.10	4.72
	(2) Diluted	1.17	1.34	1.24	4.10	4.72
See accompanying notes to the financial results

Anuh Pharma LTD

---

STATEMENT OF ASSETS AND LIABILITIES

(Rs. in Lakhs)

PARTICULARS	As at 31st March, 2026	As at 31st March, 2025
		Audited	Audited
I	ASSETS
1	Non-current Assets
	(a) Property,Plant and equipment	4,799.41	4,957.75
	(b) Capital work-in-progress	-	27.15
	(c) Intangible Assets	52.89	12.08
	(d) Right of use assets	809.77	851.65
		5,662.07	5,848.63
	(e) Financial Assets
	(i) Investments	3,958.26	5,195.48
	(ii) Loans and Advances	9.00	16.00
	(ii) Other Financial Assets	583.92	1,576.31
	(f) Deferred Tax Assets (Net)	386.20	208.03
	(g) Other Non Current Assets	5.78	201.32
Total Non-Current Assets	10,605.23	13,045.77
2	Current Assets
	(a) Inventories	14,775.50	7,448.09
	(b) Financial Assets
	(i) Investments	4,485.97	5,385.75
	(ii) Trade receivables	23,863.28	21,586.73
	(iii) Cash and cash equivalents	805.97	1,955.73
	(iv) Other Bank balances	24.18	17.77
	(v) Loans and Advances	82.64	54.73
	(vi) Other financial assets	94.11	28.84
	(c) Other current assets	999.91	1,139.36
Total Current Assets		45,131.56	37,617.00
TOTAL ASSETS		55,736.79	50,662.77
II	EQUITY AND LIABILITIES
	EQUITY
	(i) Equity Share Capital	5,011.20	2,505.60
	(ii) Other Equity	30,211.04	30,096.88
TOTAL EQUITY		35,222.24	32,602.48
Liabilities
1	NON-CURRENT LIABILITIES
	(a) Financial Liabilities	-	5.83
	(i) Lease Liabilities	214.22	203.10
	(b) Provisions	214.22	208.93
TOTAL NON-CURRENT LIABILITIES
2	CURRENT LIABILITIES
	(a) Financial Liabilities
	(i) Borrowings	-	1,049.81
	(ii) Lease Liabilities	5.83	33.00
	(iii) Trade Payables:
	Due to Micro and Small Enterprises	233.51	144.22
	Due to other than Micro and Small Enterprises	18,532.21	15,540.27
	(iv) Other financial liabilities	767.39	692.67
	(b) Other current liabilities	503.27	319.92
	(c) Provisions	26.50	16.72
	(d) Current Tax Liabilities(Net)	231.62	54.75
	TOTAL CURRENT LIABILITIES	20,300.33	17,851.36
TOTAL EQUITY AND LIABILITIES		55,736.79	50,662.77

---

Notes:-

1. The financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2. The results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 20th May, 2026. These results have been subjected to audit by statutory auditors who have expressed an unqualified opinion.

3. Other Financial indicators
   (Rs. in Lakhs)

Particulars	3 months ended 31/03/2026	3 months ended 31/12/2025	3 months ended 31/03/2025	12 months ended 31/03/2026	12 months ended 31/03/2025
	Audited (Refer Note No 7)	Unaudited	Audited (Refer Note No 7)	Audited	Audited
EBITDA	1,862.82	2,091.03	2,006.92	6,607.59	7,036.40
% of EBITDA Margin	9.22	10.60	10.13	8.56	10.64
EBITDA (Adjusted to FOREX Gain / Loss and Other Income)	2,356.39	1,991.56	2,152.09	6,784.23	6,369.00
% of Adjusted EBITDA Margin	11.66	10.10	10.86	8.79	9.63

1. During the quarter ended September 30, 2025 the shareholders of the company have approved, through the postal ballot, the issuance of the bonus shares, in the proportion of 1:1 i.e. 1(one) bonus equity share of Rs 5 each for every 1(one) fully paid up equity share held on as on the record date. Accordingly, the company has allotted 5,01,12,000 as a bonus shares on 16th July, 2025 by utilization of General reserves. All the shares and per share information in the financial results reflect the effect of the bonus share issuance.

2. The Board of Directors of the Company has recommended a final dividend of Rs. 1.50/- per equity share of face value of Rs.5 /- each (30%), subject to shareholders' approval in the forthcoming Annual General Meeting.

3. Effective 21st November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The company has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs.48.31 Lakhs primarily arising due to change in the definition of "wages" for employees.

4. The figures for the quarter ended 31st March, 2026 and 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.

5. Other income for the quarter ended 31st March 2026 includes mark to market loss on investment of ₹.189.77 Lakhs.

6. The Company does not have any subsidiary/associate/joint ventures as on 31st March 2026.

7. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

8. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Ltd.

Ritesh Shah
Joint Managing Director
(DIN: 02496729)

Place : Mumbai
Date : 20th May, 2026

---

ANUH PHARMA LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March, 2026

(Rs. in Lakhs)

Particulars		As at 31st March, 2026		As at 31st March, 2025
		Audited		Audited
(A)	CASH FLOW FROM OPERATING ACTIVITIES:
	NET PROFIT BEFORE TAX		5,422.14		6,100.53
	Adjustment for:
	Depreciation and Amortization	1,138.22		873.94
	Finance Costs	47.23		61.93
	Interest Income	(60.50)		(143.64)
	Property, Plant and Equipment W/Off / Discarded	-		0.05
	Foreign Exchange (Gain)/Loss (Unrealised)	288.72		12.29
	Market to Market (gain) / loss on investment (Net)	476.40		(492.98)
	Market to Market loss / (gain) on Derivative (Net)	-		20.80
	Sundry Credit Balance Written Back	(38.36)		(97.81)
	Fair Valuation on Unquoted Equity Share	91.43		94.22
	Dividend Income	(5.46)		(4.35)
	(Profit)/Loss on Sale of Property,Plant and Equipment (Net)	(9.42)		(1.72)
	(Profit)/Loss on Sale of Investment (Net)	(836.18)		(289.99)
			1,092.08		32.74
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES		6,514.22		6,133.27
	Adjustment for:
	Trade and Other Receivables	(1,994.52)		(2,711.58)
	Inventories	(7,327.41)		91.93
	Other Financial Assets	985.98		63.01
	Loans and Advances	(20.90)		7.04
	Other Current Assets	135.68		(534.60)
	Trade Payables	2,396.90		1,770.41
	Other Financial Liabilities	125.11		64.21
	Other current Liabilities	208.08		(59.03)
			(5,491.08)		(1,308.61)
	CASH GENERATED FROM OPERATIONS		1,023.14		4,824.66
	Direct Taxes paid (Net)	(1,324.30)	(1,324.30)	(1,112.19)	(1,112.19)
NET CASH FROM OPERATIONS		(301.16)		3,712.47
(B)	CASH FLOW FROM INVESTING ACTIVITIES:
	Sale of Investments	8,183.03		3,296.69
	Purchase of Investments	(5,676.32)		(3,418.12)
	Purchase of Property,Plant and Equipment and Capital Work in Progress	(786.85)		(1,996.29)
	Sale of Property,Plant and Equipment	9.86		(18.29)
	Interest Income	48.97		140.72
	Dividend Income	5.46		4.35
	NET CASH GENERATED/(USED IN) INVESTING ACTIVITIES		1,784.15		(1,990.94)
(C)	CASH FLOW FROM FINANCING ACTIVITIES:
	Total Proceeds from Borrowings (net of repayments):
	Secured Loans/Short Term Borrowings	(1,049.81)		848.47
	Payment of Lease Liabilities	(35.41)		(34.64)
	Finance Costs	(50.58)		(47.58)
	Dividend paid (Including Tax thereon)	(1,496.95)		(1,252.22)
	NET CASH (USED IN) FROM FINANCING ACTIVITIES		(2,632.75)		(485.97)
	NET INCREASE IN CASH AND CASH EQUIVALENTS (A + B + C)		(1,149.76)		1,235.56
	CASH AND CASH EQUIVALENT AS AT THE BEGINNING OF THE PERIOD		1,955.73		720.17
	CASH AND CASH EQUIVALENT AS AT THE END OF THE PERIOD		805.97		1,955.73

Anuh Pharma Limited

---

3

ANUH PHARMA LTD.

Registered Office : 3-A Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400 018 INDIA.
Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500
E-Mail: anuh@sk1932.com • CIN: L24230MH1960PLC011586
Web: www.anuhpharma.com

Date: 20th May, 2026

To,

The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

BSE Scrip Code: 506260

To,

Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051
NSE Symbol: ANUHPHR; Series: EQ

Ref: Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Subject: Declaration of unmodified opinion on Audited Financial Results

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we hereby declare that the Statutory Auditors of Anuh Pharma Limited, Jayantilal Thakkar & Co., Chartered Accountants (Firm Registration No.: 104133W), have submitted their Report with unmodified opinion on Audited Financial Results of the Company for the financial year ended March 31, 2026, as approved by the Board of Directors in its Meeting held today i.e. May 20, 2026.

This is for your information and record.
Thanking you,

FOR ANUH PHARMA LIMITED

RITESH BIPIN SHAH
JOINT MANAGING DIRECTOR
(DIN: 02496729)

SE
We Serve Since 1932
Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
Annexure - B
111 (A) MAHATMA GANDHI ROAD,
FORT, MUMBAI - 400 023.
Telephones: (91-22) 2265 8800
(91-22) 2265 8900
E-Mails: jtco23@jtco.co.in
office@jtco.co.in
Website: www.jtco.co.in

Independent Auditor's Report on Audit of Quarterly and Annual Audited Financial Results of Anuh Pharma Limited (the "Company") Pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Anuh Pharma Limited

Report on the audit of the Financial Results

Opinion

We have audited the accompanying statement of quarterly and annual financial results of Anuh Pharma Limited (the "Company") for the quarter ended 31st March, 2026 and for the year ended 31st March, 2026 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

i. is presented in accordance with the requirements of the Listing Regulation 33 in this regard; and
ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules 2015 and other accounting principles generally accepted in India, of the net profit after tax and other comprehensive income and other financial information of the Company for the quarter ended 31st March, 2026 and for the year ended 31st March, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

A

---

JAYANTILAL THAKKAR & CO. CHARTERED ACCOUNTANTS
Continuation Sheet No. 2
Date

Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive loss of the Company and other financial information in accordance with the recognition and measurement principles laid down in the Indian accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs specified under section 143(10) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

CHARTERED ACCOUNTANTS

---

JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
Continuation Sheet No. 3
Date

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
• Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
• Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
• Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended 31st March, 2026 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our opinion on the Statement is not modified in respect of this matter.

For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)

DILIP J. THAKKAR
PARTNER
MEMBERSHIP NO. 005369
UDIN: 26005369ISYRLX8618

PLACE: Mumbai
DATE: 20th May, 2026

---

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,

Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.

Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500

Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586

Web: www.anuhpharma.com

Annexure - C

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Details of events that need to be Provided	Information of such events
a)	reason for change viz. appointment, re-appointment, resignation,—removal, death or otherwise	Mr. Bipin Nemchand Shah (DIN: 00083244), has been re-appointed as Non-Executive Non-Independent Director, subject to the approval of members in the Annual General Meeting, who was liable to retire by rotation being re-appointed in terms of Section 152 (6) of the Companies Act, 2013.
b)	date of appointment / re-appointment/ cessation — (as applicable)	12th August, 2026.
c)	term of appointment / re-appointment	Re-appointed as per the provisions of Section 152(6) of the Companies Act, 2013.
d)	brief profile (in case of appointment)	Mr. Bipin Shah is a Chemical Engineer by qualification. He is the Vice Chairman of Anuh Pharma Ltd., a leading bulk drug manufacturing Company and is also Director / Partner in other SK Group of Companies / Firms, who are in the pharmaceutical industry since last 90 years and he is responsible for distribution, C & F and Mother Depot operations of the group. He has a vast experience of nearly 50 years in the pharmaceutical field and is widely travelled. His specific area of interest has been marketing and management. He is currently the President of Thane Belapur Industries Association and he is a Managing Committee Member of Indian Merchant Chambers, Mumbai.
e)	disclosure of relationships between directors (in case of appointment of a director)	Mr. Bipin Shah is brother of Mr. Bharat Shah (Non-Executive Director). Mr. Bipin Shah is father of Mr. Ritesh Shah (Joint Managing Director) and Mr. Vivek Shah (Joint Managing Director).
f)	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/ 2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Mr. Bipin Shah is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

SK

We Serve Since 1932

Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,

Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.

Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500

Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586

Web: www.anuhpharma.com

Annexure - D

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Details of events that need to be Provided	Information of such events
a)	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Mr. Arun Todarwal (DIN: 00020916), has been re-appointed as Non-Executive Non-Independent Director, subject to the approval of members in the Annual General Meeting, who was liable to retire by rotation being re-appointed in terms of Section 152 (6) of the Companies Act, 2013.
b)	date of appointment / re-appointment/cessation (as applicable)	12th August, 2026.
c)	term of appointment / re-appointment	Re-appointed as per the provisions of Section 152(6) of the Companies Act, 2013.
d)	brief profile (in case of appointment)	Mr. Arun Todarwal is a fellow member of the Institute of Chartered Accountants of India. He has been practicing as a Chartered Accountant since 1981. During his years of practice, he has handled various professional assignments including Statutory Audits, Internal Audits, Management and Systems Audits, Due diligences, Taxation, International Taxation, Joint Ventures, etc. He is well-versed in Tax matters and has travelled abroad on several occasions to deliver talks on Indian Taxation as well as Investment in India. Mr. Arun Todarwal is also a member of the Institute of Internal Auditors, National Centre for Quality Management, Bombay Management Association and Bombay Chartered Accountants Society. His vast experience has put him on panel of Auditors with the Registrar of Co-operatives Societies and the Official Liquidator, Mumbai High court.
e)	disclosure of relationships between directors (in case of appointment of a director)	There is no inter-se relationship among the Directors.
f)	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/ 2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Mr. Arun Todarwal is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

S

We Serve Since 1932

Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.
Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500
Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586
Web: www.anuhpharma.com

Annexure - E

Brief Profile of Mr. P. N. Rao as General Manager - Quality

Sr. No.	PARTICULARS	PROFILE
1	Reason for change viz.
Appointment, re-appointment resignation, removal, death or otherwise.	Appointment as General Manager - Quality
2	Date of appointment /re-appointment/cessation (as applicable) and terms of appointment	Appointment w.e.f. 01st June, 2026 on the terms mentioned in the letter of appointment.
3	Brief Profile (in case of appointment)	Mr PN Rao brings 23+ years of experience in quality leadership within pharmaceutical manufacturing, with strong expertise in QMS implementation, regulatory compliance, and audit management. He has handled major regulatory inspections, driven process improvements through Lean Six Sigma, and implemented digital quality systems.
4	Disclosure of Relationships between Directors (in case of appointment of Director)	Not applicable

S

We Serve Since 1932

Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,

Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.

Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500

Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586

Web: www.anuhpharma.com

Annexure – F

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Details of events that need to be Provided	Information of such events
a)	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of M/s. RMJ & Associates LLP., Chartered Accountants (Firm Registration No.: W100281), as Internal Auditors of the Company.
b)	date of appointment / re-appointment/ cessation & term of appointment / re-appointment	The Board at its meeting held on May 20, 2026, has approved the appointment of M/s. RMJ & Associates LLP., Chartered Accountants (Firm Registration No.: W100281) M/s. RMJ & Associates LLP., Chartered Accountants are appointed as Internal Auditors for the FY 2026-27.
c)	brief profile (in case of appointment)	M/s. RMJ & Associates LLP, Chartered Accountants, is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India ("ICAI").
It is specialized in providing services in the areas of audit & assurance, direct and indirect tax, business advisory, accounting and regulatory compliances. With three locations in Mumbai, Ahmedabad and Pune and a vibrant team of 100 plus team members lead by 6 Partners having rich experience in their area of domain.
d)	disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

SK

We Serve Since 1932

Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,

Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.

Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500

Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586

Web: www.anuhpharma.com

Annexure - G

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Details of events that need to be Provided	Information of such events
a)	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Ankit Kishor Chande, Cost Accountants (Membership No.: 34051; Firm Registration No.: 102660), as Cost Auditors of the Company
b)	date of appointment / re-appointment/ cessation (as applicable) & term of appointment / re-appointment	The Board at its meeting held on May 20, 2026, has approved the appointment of Ankit Kishor Chande, Cost Accountant (Membership No.: 34051; Firm Registration No.: 102660), as Cost Auditors for the FY 2026-27, subject to approval of the Shareholders.
Ankit Kishor Chande, Cost Accountant are appointed as Cost Auditor for the Financial Year 2026-27.
c)	brief profile (in case of appointment)	Ankit Kishor Chande (Membership No.: 34051; Firm Registration No.: 102660) who is a Qualified Cost Accountant having his firm of Cost & Management Accountants registered with the Institute of Cost Accountants of India rendering services in the areas of Costing, Audit & Assurance, Consulting Advisory & Finance and has a total experience of more than 13 years.
The firm has served to as many as 17 different industries and has a rich experience of Pharmaceutical, Chemical & Construction Industry.
d)	disclosure of relationships between directors (in case of appointment of a director)	NA

SK

We Serve Since 1932

Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75

---

3

ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.
Tel.: +91-22-6622 7575 • Fax: +91-22-6622 7600 / 7500
Email: anuh@sk1932.com • CIN: L24230MH1960PLC011586
Web: www.anuhpharma.com

Annexure - H

Pursuant to the Regulation 30(5) of the SEBI Listing Regulations, as amended, and the Company's Policy for Determining Materiality of Information for Disclosure to Stock Exchanges, we wish to inform that the Board of Directors of the Company have authorized the Key Managerial Personnel ("KMP") of the Company to determine the materiality of an event or information and for the purpose of making the necessary disclosures to the stock exchanges under Regulation 30 of SEBI Listing Regulations. The details of the KMPs of the Company are as under

SN.	Name of the Key Managerial Personnel	Address & Contact Details	Purpose
1.	Mr. Ritesh Bipin Shah	Address: 3-A, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018.
Tel: (+91) 22 66227575; Ext: 508
Email: ritesh@anuhpharma.com
Website: www.anuhpharma.com	Determine materiality and disclosures to be made to the exchange
2.	Mr. Manan Jayesh Vadhan	Address: 3-A, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018.
Tel: (+91) 22 66227575; Ext: 562
Email: aplcs@sk1932.com
Website: www.anuhpharma.com

SEBI

We Serve Since 1932

Factory: E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. Tel.: +91-7410055574 / 75